Filing Flows › Azenta (AZTA) › Q2 FY26 › vs Q1 FY26
Azenta (AZTA) Q2 FY26 vs Q1 FY26 (quarter over quarter)
Azenta's revenue fell $3.8M (-3%) from $149M in Q1 FY26 to $145M in Q2 FY26. The biggest changes: Multiomics −$3.5M (-5%); Sample Management Solutions −$334K (-0.4%).
Azenta, Q2 FY26: revenue $145M (+1% year over year), operating margin -114.5%, net loss $161M, operating cash flow $13.5M. The chart draws each line against Q1 FY26, the increases inside each band.
Margins
| Q2 FY26 | Q1 FY26 | Change | |
|---|---|---|---|
| Free cash flow margin | 4.2% | 9.9% | -5.6 pts |
Every line
| Line | Q2 FY26 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Core Products | $44.3M | $47.6M | −$3.3M | -7% |
| Sample Repository Services | $36.8M | $33.8M | $3.0M | +9% |
| Sample Management Solutions | $81.1M | $81.4M | −$334K | -0.4% |
| Multiomics | $63.7M | $67.2M | −$3.5M | -5% |
| Revenue | $145M | $149M | −$3.8M | -3% |
| Other income, net | $4.7M | −$5.1M | $9.7M | — |
| Income tax benefit | $323K | −$3.1M | $3.5M | — |
| Net loss | $161M | $15.4M | $145M | +942% |
| Costs & expenses | $311M | $164M | $147M | +89% |
| Operating costs | $311M | $156M | $155M | +99% |
| Cost of revenue | $82.8M | $84.9M | −$2.2M | -3% |
| Research & development | $9.4M | $9.2M | $244K | +3% |
| SG&A | $67.9M | $60.6M | $7.3M | +12% |
| Other operating costs | $151M | $1.1M | $149M | 132× |
| Operating cash sources | $174M | $36.3M | $138M | +380% |
| Depreciation & amortization | $14.0M | $13.6M | $354K | +3% |
| Share-based compensation | $6.4M | $4.1M | $2.3M | +57% |
| Working capital & other | $154M | $18.6M | $135M | +729% |
| Net loss absorbed | $161M | $15.4M | $145M | +942% |
| Operating cash flow | $13.5M | $20.8M | −$7.3M | -35% |
| Free cash flow (OCF − capex) | $6.1M | $14.7M | −$8.5M | -58% |
| Capital expenditures | $7.4M | $6.2M | $1.2M | +20% |
Questions
How much did Azenta's revenue grow quarter over quarter in Q2 FY26?
Azenta's revenue fell $3.8M (-3%) from $149M in Q1 FY26 to $145M in Q2 FY26.
What drove Azenta's revenue change in Q2 FY26?
Multiomics −$3.5M (-5%); Sample Management Solutions −$334K (-0.4%).